Shouyao Holdings (Beijing) Co. Ltd. A

Shouyao Holdings released its 2026 interim report on August 28. First-half operating revenue was 28 million yuan, up 1,300 percent year on year. Net profit attributable to the parent narrowed from a loss of 104 million yuan in the same period last year to a loss of 61.06 million yuan. Net profit attributable to the parent after deducting non-recurring items narrowed from a loss of 114 million yuan to a loss of 67.18 million yuan. Net operating cash flow was negative 66.59 million yuan, an improvement of 41.4 percent year on year. Earnings per share were negative 0.4106 yuan. As of the end of the second quarter, total assets stood at 726 million yuan, down 8.3 percent from the end of the previous year, and net assets attributable to the parent stood at 619 million yuan, down 9.0 percent. The company's first self-developed ALK inhibitor, Conteltinib granules, received marketing approval on June 11, 2026, marking the company's transition from the research and development stage to the commercialization stage. A product developed in cooperation with Chia Tai Tianqing also obtained marketing authorization. In addition, the registration review of SY-5007 made important progress, with pivotal Phase III study data presented at the 2026 ASCO annual meeting. Two registration studies for the third-generation ALK inhibitor SY-3505 are also advancing.

The innovative drug sector opened lower on July 6 before climbing higher in choppy trade. Shouyao Holdings surged by the 20 percent daily limit, Maiwei Bio and Shutaishen jumped over 10 percent, BeiGene rose more than 6 percent, and Asymchem and Hengrui Medicine gained over 4 percent. On the news front, the General Office of the National Medical Products Administration recently sought public comments on a draft notice regarding optimizing the review and approval of cell and gene therapy drugs. The draft mentions supporting clinically driven innovation in cell and gene therapy drug development, focusing on key areas such as malignant tumors and rare diseases, encouraging global simultaneous development, and including eligible cell and gene therapy drugs in a 30-day review and approval channel for innovative drug clinical trials. A research note from Orient Securities noted that Chinese companies have recently made gradual breakthroughs in frontier fields such as cell therapy and AI-driven drug discovery. Several innovative drug makers have seen their core products enter the harvest stage, while medical insurance access, commercial insurance coverage, and cost ratio optimization are jointly driving continuous profit improvement.

China's A-share market saw mixed performance on July 6, with the Shanghai Composite Index edging down 0.06 percent to 4,041.24 points and the ChiNext Index falling 1.77 percent. Combined turnover on the two exchanges reached approximately 3.11 trillion yuan. The coal sector rallied in the afternoon, with Haohua Energy hitting its daily limit at the close, Xinji Energy surging nearly 9 percent, and Shaanxi Coal Industry climbing over 7 percent. The pharmaceutical sector was strong, with innovative drug concepts standing out. Shouyao Holdings briefly surged by the 20 percent daily limit, and Gan & Lee Pharmaceuticals hit its daily limit. The PCB concept slumped sharply, with Sinoma Science & Technology, China Jushi, and Haohua Science & Technology all hitting their daily limit down. Reports indicate that Nvidia's next-generation Kyber NVL144 rack architecture may face delivery delays of more than 12 months due to manufacturing process challenges with PCB mid-boards, pushing mass production back to 2028.